Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Asthma is now recognized as an inflammatory disease associated with eosinophil infiltration into the pulmonary tissue. It has appeared in recent years that phosphodiesterase type IV inhibitors presented all the necessary characteristics to be used as new anti-asthmatic drugs. Indeed, in addition to their bronchodilator properties, they have inhibitory activities on inflammatory cell infiltration into the lung and on inflammatory mediator release. However, the mechanism of action of phosphodiesterase inhibitors, theoretically linked to the increase in intracellular cAMP, is now largely open for discussion.
Lagente
V
V
Laboratoire de Pharmacodynamie, Faculté des Sciences, Pharmaceutiques et Biologiques, Université de Rennes I, France.
Hichami
A
A
Boichot
E
E
Martins
M A
MA
Silva
P M
PM
D015105:3',5'-Cyclic-AMP Phosphodiesterases; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D000893:Anti-Inflammatory Agents; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D000242:Cyclic AMP / Q000502:physiology; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004804:Eosinophils / Q000502:physiology; D006168:Guinea Pigs; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000502:physiology; D011760:Pyrrolidinones / Q000494:pharmacology; D020889:Rolipram; D013806:Theophylline / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D013806:Theophylline; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram